Delivery Order SPE2DB20D1004-SPE2DB24FF4T2

Award Date 2/23/24
Potential Completion Date 2/26/24
Potential Value $4.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of Sucralfate 1 GM/10 ML Suspension in 420 ML bottles. The contract, valued at $8,380.29, is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, worth up to $999,999,999 and extending through November 2026. The IDC covers a broad range of pharmaceutical products and medical supplies to support military healthcare programs...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,730.56, is for the supply of Sucralfate 1 gm/10 ml suspension in 420 ml bottles. The contract is a Firm Fixed Price arrangement with no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, valued at $3,590.93, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of Sucralfate 1 GM/10 ML Suspension in 420 ML containers. No set-aside designation was used for this contract. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,339.50, is for the delivery of Sucralfate 1 GM/10 ML Suspension in 420 ML quantities. The contract has an ultimate completion date of October 30, 2023 and is a firm fixed-price delivery order. This contract is not designated as a set-aside. Amerisourcebergen Drug Corp is a subsidiary of the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $2,246.16 firm fixed-price delivery order is for the supply of 420 milliliters of Sucralfate 1 gram per 10 milliliters suspension to support federal healthcare programs. The contract has an ultimate completion date of November 20, 2023 and was awarded on November 17, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract...
The federal contract award is for the delivery of Sucralfate 1 GM/10 ML Suspension in 420 ML quantities. The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., by the Defense Logistics Agency (DLA). The contract is a Delivery Order valued at $1,455.06 with a Firm Fixed Price pricing type. The period of performance runs through May 16, 2023. This contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,500.49 firm-fixed-price contract is for the supply of Sucralfate 1 GM/10 ML Suspension, a medication used to treat and prevent certain types of ulcers. The contract has a completion date of September 26, 2023 and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award, valued at $4,144.35, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Sucralfate 1 GM/10 ML Suspension, a pharmaceutical product, to support military healthcare programs. The contract is a Delivery Order (DO) under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued up to $999,999,999.00 and running through November...
This federal contract award is for the delivery of Sucralfate 1 GM/10 ML Suspension, with a total value of $1,653.39. The contract was awarded by the Defense Logistics Agency (DLA) to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 between Cencora, Inc. and the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $28,215.64 firm fixed-price delivery order contract is for the supply of Sucralfate 1 GM tablets, a medication used to treat certain gastrointestinal conditions. The contract has an ultimate completion date of October 31, 2023 and does not have a set-aside designation, indicating open competition....
  • SPE2DB20D1004
    Indefinite Delivery Contract
  • SPE2DB20D1004-SPE2DB24FF4T2
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of 420 ml bottles of 1 gm/10 ml sucralfate suspension. The $4,416.88 firm fixed-price delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) the company holds with DLA Troop Support Medical to provide a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract, which runs through November 2026, encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. This particular delivery order does not have a set-aside designation, indicating open competition.

Generated 5/14/25, 10:41 AM